

No	Subject	Register number	SENDER	Release? YES/Partial/ NO/Public	Reason/Exception (*) (if no/partial release)
1	AstraZeneca vaccine - Binding Allocation per Member State	Ares(2021)3748178	SANTE	PARTIAL	Commercial interest - Article 4(2), first indent;
2	BioNTech/Pfizer vaccine - Allocation per Member State	Ares(2021)1584797	SANTE	PARTIAL	Commercial interest - Article 4(2), first indent;
3	BioNTech-Pfizer Allocation Additional Order	Ares(2021)1583927	SANTE	PARTIAL	Commercial interest - Article 4(2), first indent;
4	BioNTech-Pfizer Allocation Additional Order - VERSION 2	Ares(2021)1583706	SANTE	PARTIAL	Commercial interest - Article 4(2), first indent;
5	BioNTech-Pfizer Allocation Additional Order - VERSION 3	Ares(2021)1583780	SANTE	PARTIAL	Commercial interest - Article 4(2), first indent;
6	BioNTech-Pfizer Consolidated Contract #1 Options Contract#2 Initial_Allocation	Ares(2021)1637057	SANTE	PARTIAL	Commercial interest - Article 4(2), first indent;
7	BioNTech-Pfizer Contract#2_Initial Doses Allocation	Ares(2021)1637057	SANTE	PARTIAL	Commercial interest - Article 4(2), first indent;
8	BioNTech/Pfizer Contract #2 - Allocation per Participating Member State - Optional Doses	Ares(2021)2310708	SANTE	PARTIAL	Commercial interest - Article 4(2), first indent;
9	BioNTech/Pfizer Contract #2 - Allocation per Participating Member State (acceleration) - Optional Doses	Ares(2021)5744862	SANTE	PARTIAL	Commercial interest - Article 4(2), first indent;
10	BioNTech Pfizer 3rd contract - Allocation table	Ares(2021)5705305	SANTE	PARTIAL	Commercial interest - Article 4(2), first indent;
11	Curevac - Allocation per Member State of the Initial European Doses	Ares(2021)1585725	SANTE	PARTIAL	Commercial interest - Article 4(2), first indent;
12	Janssen vaccine - Allocation per Participating Member State (Initial doses)	Ares(2021)5705226	SANTE	PARTIAL	Commercial interest - Article 4(2), first indent;
13	Janssen - Additional Volume (first tranche) and Allocation per Exercising Member State	Ares(2021)3748734	SANTE	PARTIAL	Commercial interest - Article 4(2), first indent;
14	Moderna - Allocation Table Initial and Optional doses - Letter Commissioner and Annex	Ares(2020)7701751	SANTE	PARTIAL	Commercial interest - Article 4(2), first indent;
15	Moderna - Allocation Table v2	Ares(2021)1637949	SANTE	PARTIAL	Commercial interest - Article 4(2), first indent;
16	Moderna - Purchase Agreement SANTE/2021/C3/010 - Allocation Table Additional Doses	Ares(2021)3749152	SANTE	PARTIAL	Commercial interest - Article 4(2), first indent;
17	[CORRIGENDUM] Purchase Agreement Option Increase - Allocation Table	Ares(2021)4021020	SANTE	PARTIAL	Commercial interest - Article 4(2), first indent;
18	Novavax Fixed Initial Doses	Ares(2021)6216853	SANTE	PARTIAL	Commercial interest - Article 4(2), first indent;
19	Novavax Flexible Initial Doses Q1	Ares(2022)1115395	SANTE	PARTIAL	Commercial interest - Article 4(2), first indent;
20	Novavax Flexible Initial Doses Q2	Ares(2022)1115395	SANTE	PARTIAL	Commercial interest - Article 4(2), first indent;
21	Sanofi Final Allocation - Total amount of doses and breakdown by MS	Ares(2021)7349416	SANTE	PARTIAL	Commercial interest - Article 4(2), first indent;
22	Pfizer BioNTech - Advance Purchase Agreement for the development, production, priority-purchasing options and supply of a successful COVID-19 vaccine for EU Member States number SANTE/2020/C3/043	Ares(2021)256798	SANTE	PARTIAL	Personal data -Article 4(1)(b); Commercial interest - Article 4(2), first indent;
23	Pfizer BioNTech - Purchase Agreement for further development, production, purchasing options and supply of the successful COVID-19 vaccine for EU Member States number SANTE/2021/C3/005	Ares(2021)1601544	SANTE	PARTIAL	Personal data -Article 4(1)(b); Commercial interest - Article 4(2), first indent;
24	Pfizer BioNTech - Purchase Agreement for the further development, production, purchasing options and supply of COVID-19 vaccines for EU Member States number SANTE/2021/03/010	Ares(2021)3404228	SANTE	PARTIAL	Personal data -Article 4(1)(b); Commercial interest - Article 4(2), first indent;
25	Moderna - Advance Purchase Agreement for the production, priority-purchasing options and supply of a successful COVID-19 vaccine for EU Member States number SANTE/2020/C3/054	Ares(2021)256592	SANTE	PARTIAL	Personal data -Article 4(1)(b); Commercial interest - Article 4(2), first indent;

26	Moderna - Purchase Agreement for the production, priority-purchasing options and supply of a successful COVID-19 vaccine for EU Member States number SANTE/2021/C3/020	Ares(2021)1601566	SANTE	PARTIAL	Personal data -Article 4(1)(b); Commercial interest - Article 4(2), first indent;
27	Curevac - Advance Purchase Agreement for the development, production, advance purchase and supply of a COVID-19 vaccine for EU Member States number SANTE/2020/C3/049	Ares(2021)256728	SANTE	PARTIAL	Personal data -Article 4(1)(b); Commercial interest - Article 4(2), first indent;
28	AstraZeneca - Advance Purchase Agreement for the production, purchase and supply of a COVID-19 vaccine in the European Union number SANTE/2020/C3/037	Ares(2020)4440071	SANTE	PARTIAL	Personal data -Article 4(1)(b); Commercial interest - Article 4(2), first indent;
29	Sanofi/GSK - Advance Purchase Agreement for the development, production, priority-purchasing options and supply of a successful COVID-19 vaccine for EU Member States number SANTE/2020/C3/042	Ares(2020)4855182	SANTE	PARTIAL	Personal data -Article 4(1)(b); Commercial interest - Article 4(2), first indent;
30	Janssen - Advance Purchase Agreement for the purchase and supply of a COVID-19 vaccine for EU Member States number SANTE/2020/C3/047	Ares(2020)5806059	SANTE	PARTIAL	Personal data -Article 4(1)(b); Commercial interest - Article 4(2), first indent;
31	Novavax - Advance Purchase Agreement for the development, production, priority-purchasing options and supply of a successful COVID-19 vaccine for EU Member States number SANTE/2020/C3/087	Ares(2021)6475411	SANTE	PARTIAL	Personal data -Article 4(1)(b); Commercial interest - Article 4(2), first indent;
32	ANNEX to the Commission Decision on approving the agreement with Member States on procuring Covid-19 vaccines on behalf of the Member States and related procedures C(2020) 4192 final	N/A	EC	PUBLIC	N/A

(*) Indicates applicable exception in Art. 4 of Regulation (EC) 1049/2001